1. Continuing Exposure to Low-Dose Nonylphenol Aggravates Adenine-Induced Chronic Renal Dysfunction and Role of Rosuvastatin Therapy
- Author
-
Yen Chia-Hung, Sun Cheuk-Kwan, Leu Steve, Wallace Christopher, Lin Yu-Chun, Chang Li-Teh, Chen Yung-Lung, Tsa Tzu-Hsien, Kao Ying-Hsien, Shao Pei-Lin, Hsieh Chi-Ying, Chen Yen-Ta, and Yip Hon-Kan
- Subjects
Medicine - Abstract
Abstract Background Nonylphenol (NP), an environmental organic compound, has been demonstrated to enhance reactive-oxygen species (ROS) synthesis. Chronic exposure to low-dose adenine (AD) has been reported to induce chronic kidney disease (CKD). Methods In this study, we tested the hypothesis that chronic exposure to NP will aggravate AD-induced CKD through increasing generations of inflammation, ROS, and apoptosis that could be attenuated by rosuvastatin. Fifty male Wistar rats were equally divided into group 1 (control), group 2 (AD in fodder at a concentration of 0.25%), group 3 (NP: 2 mg/kg/day), group 4 (combined AD & NP), and group 5 (AD-NP + rosuvastatin: 20 mg/kg/day). Treatment was continued for 24 weeks for all animals before being sacrificed. Results By the end of 24 weeks, serum blood urea nitrogen (BUN) and creatinine levels were increased in group 4 than in groups 1–3, but significantly reduced in group 5 as compared with group 4 (all p Conclusion NP worsened AD-induced CKD that could be reversed by rosuvastatin therapy.
- Published
- 2012
- Full Text
- View/download PDF